# A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LWP779 in Healthy Participants

> **NCT07371455** · PHASE1 · RECRUITING · sponsor: **Longwood Pharmaceuticals (Hangzhou) Co., Ltd.** · enrollment: 76 (estimated)

## Conditions studied

- Ischemic Stroke

## Interventions

- **DRUG:** LWP779
- **DRUG:** Placebo of LWP779

## Key facts

- **NCT ID:** NCT07371455
- **Lead sponsor:** Longwood Pharmaceuticals (Hangzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-13
- **Primary completion:** 2026-07-10
- **Final completion:** 2026-09-30
- **Target enrollment:** 76 (ESTIMATED)
- **Last updated:** 2026-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07371455

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07371455, "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LWP779 in Healthy Participants". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07371455. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*